权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Association of gene polymorphisms of hypertension-related vasoactive substances with hypertension and response to the antihypertensive drugs

高血压相关血管活性物质基因多态性与高血压及降压药物反应的关系

基本信息

批准号：
16590433
负责人：
TOTSUNE Kazuhito
金额：
$ 2.24万
依托单位：
Tohoku University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2004
资助国家：
日本
起止时间：
2004 至 2006
项目状态：
已结题

项目摘要

In the present study, association of gene polymorphisms of hypertension-related vasoactive substances with hypertension and blood pressure-lowering efficacy of the antihypertensive drugs was investigated.Results :1.Type-1 angiotensin II receptor (AT1R) gene polymorphism AT1R/A1166C was analyzed and we found that there was little association between the polymorphism and blood pressure in the general Japanese population (Hypertens Res 27:551-556, 2004). There was little association between the polymorphism and pressure- lowering efficacy of the antihypertensive drugs.2. Urotensin II (UTII) and urotensin II-related peptide (URP) gene polymorphism was investigated. We found the results indicating that UTII has a significant association with blood pressure (reported in Japanese Renal Association Meeting in 2006), but not URP. No association was found between UTII polymorphism and pressure-lowering efficacy of the antihypertensive drugs.3. Gene polymorphism of adrenomedullin 2, a potent vasodilator peptide, was analyzed, and the results suggesting a possible association with history of heart diseases were obtained (unpublished).4. Gene polymorphism of urocortin family members was investigated. In urocortin II rs6147814 I/D polymorphism study, we found little association between the polymorphism and blood pressure. In urocortin III R91G polymorphism study, we obtained the results suggesting that R91G polymorphism had an association with white coat hypertension (reported in Renal week of American Renal Association in 2005). In corticotropin releasing factor type-2 receptor gene polymorphism study, we found a new VNTR and a significant higher night time systolic blood pressure in long allele group compared with short allele group (unpublished). No significant associations were found between any of the gene polymorphisms and pressure- lowering efficacy of the antihypertensive drugs.

结果：1.对日本人群中血管紧张素II受体(AT1R)基因AT1R/A1166C基因多态性进行了分析，发现AT1R/A1166C基因多态性与日本普通人群的血压无明显关联(Hyperten RES 27：551-556,2004)。结论：1.基因多态性与降压药物的降压疗效之间几乎没有关联。检测尾加压素II(UTII)及其相关肽(URP)基因多态性。我们发现结果表明UTII与血压显著相关(2006年日本肾脏协会会议报道)，但与URP无关。未发现UTII基因多态性与降压药物降压疗效的相关性。对肾上腺髓质素2基因的多态性进行了分析，结果提示可能与心脏病史有关(未发表)。对尿皮质素家族成员的基因多态性进行了研究。在Urocortin II rs6147814 I/D多态研究中，我们发现该多态与血压之间几乎没有关联。在Urocortin III R91G基因多态性研究中，我们得到了提示R91G基因多态性与白大衣高血压相关的结果(2005年发表在美国肾脏协会的肾周刊上)。在促肾上腺皮质激素释放因子2型受体基因的多态性研究中，我们发现了一个新的VNTR，与短等位基因组(未发表)相比，长等位基因组的夜间收缩压显著高于短等位基因组。未发现任何基因多态与降压药物降压效果之间的显著关联。